Page 739 - Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice

Index 727

for chronic renal failure, 698–699 complications of, 707 Hepatorenal syndrome, 473, 473f, 474b
clotting in, 697–698 for poisoning, 681, 689, 703–704 Hereditary hypophosphatemic rickets with
complications of, 707–709 Hemophilia, perioperative management of, 413 hypercalciuria, 200
continuous, 687–688 Hemorrhage. See also Bleeding; Coagulation Hetastarch, 336. See also Hydroxyethyl starches
delivery (dose) of, 688 defects adverse effects of, 399, 425, 490, 492
outcome and, 688 assessment of, 397 for ascites, 489–490, 492
quantification of, 683, 684–688 citrate-preserved blood and, 493 coagulopathy due to, 399, 425, 492
dialysate in colloid-related, 394 degree of volume expansion by, 652
additives for, 695 hypocalcemia and, 167 drug interactions with, 410
composition of, 693–694, 694f management of, 399 duration of action of, 652
dose of, 685 autotransfusion in, 399 perioperative use of, 423, 426
ethyl alcohol in, 695 for compressible hemorrhage, 399 physiochemical properties of, 426
temperature of, 695–696 fluid therapy in, 397. See also Fluid therapy for shock, 565t, 566, 567t
double-pool variable-volume model of, 686, for noncompressible hemorrhage, 398 Hicky-Hare test, 74
686f Hemorrhagic shock. See also Shock, High-fiber diet
for electrolyte imbalances, 702–703, 702f hypovolemic for hepatic encephalopathy, 484t
for ethylene glycol poisoning, 262, 703, assessment of, 397 for hypercalcemia, 154
705–707, 706f fluid therapy for, 334 High-potassium (HK) phenotype, 100–101
fluid and solute transport in, 680–681 autotransfusion in, 399 History, diet, 623, 624f
for fluid imbalances, 699–702 coagulopathy and, 399, 400 Hives, transfusion-related, 596, 597t
frequency of, 687–688 complications of, 398, 399 HK phenotype, 100–101
future directions for, 709 for compressible hemorrhage, 399 Homeostasis, 14–15, 15f
with hemoperfusion, 703–704 fluid selection in, 399 Human brain natriuretic peptide
for hypercalcemia, 158t, 163 for noncompressible hemorrhage, 398 for heart failure, 522t, 529
for hyperkalemia, 694, 702–703, 702f glucocorticoids for, 574 renal effects of, 522t, 525–526
for hyperphosphatemia, 695 mental status in, 397 Human serum albumin, 395, 588, 654.
indications for, 688–707 pathophysiology of, 559–561 See also Transfusion(s)
intermittent vs. continuous, 687–688 Hemothorax, perioperative management of, adverse effects of, 395, 489
monitoring of, 686–687 411 benefits of, 489
outcome and prognosis for, 708–709 Henderson equation, 235–236, 243 Humoral hypercalcemia of benignancy, 156
physical principles of, 680–681 Henderson-Hasselbalch approach Humoral hypercalcemia of malignancy,
for poisoning, 262, 703–707 to [A TOT ] disorders, 318, 327 146–147, 146f
prescription for, 688–689, 689b, 690b to PCO 2 disorders, 318, 327 Hyaluronan, 648
for renal transplantation, 699 vs. strong ion approach, 317, 318, 327 Hyaluronidase, for subcutaneous infusions, 351
single-pool fixed-volume model of, 683f, 686 Henderson-Hasselbalch equation, 206, 232, Hydralazine, for heart failure, 529
sodium profiling in, 693–694 234, 235–236 Hydration status assessment, 392
ultrafiltration in, 700–702, 701f Heparin Hydrochloric acid
urea kinetic modeling and, 684–688 for acute pancreatitis, 450 in acid-base balance, 276, 278f
urea removal by, 682–688 for blood products, 592, 592t for metabolic alkalosis, 279–280
venous oxygen saturation in, 701, 701f for disseminated intravascular coagulation, Hydrochlorothiazide
vs. peritoneal dialysis, 667, 668b 414 for central diabetes insipidus, 57
Hemodialyzers, 690, 691t for hemodialysis, 696–698, 698f for heart failure, 531–532
Hemodilution, preoperative, 406 in reduced amount, 697 Hydrocortisone, for hypoadrenocorticism, 508
Hemodynamic azotemia, 544 vs. non-heparin dialysis, 696, 697–698 Hydrogen ion balance
Hemodynamic monitoring. See also Central for peritoneal dialysis, 672–673 external, 245
venous pressure, monitoring of Heparin flushing, 373 urinary potassium excretion and, 99–100
in heart failure, 535–538, 536f Heparin-coated catheters, 354 Hydrogen ion secretion, renal tubular, 246,
Hemoglobin Hepatic encephalopathy, 478, 479b, 480t, 481f 246f
as buffer, 236–237 acid-base disorders in, 482–483 Hydrogen ions, pH and, 231–232, 232f, 233t.
cardiac index and, 407, 429 electrolyte disturbances in, 482–483 See also pH
critical concentration of, 406 episodic, 482 Hydrogen-ATPase, 97
perioperative use of, 429 hypoglycemia in, 481–483 Hydrogen-potassium ATPase, 97
Hemoglobin saturation, 406, 407 management of, 482–485 Hydrostatic pressure, 12–13, 13f
Hemoglobin solutions, 429 in acute severe disease, 483 ß-Hydroxybutyrate, in diabetic ketoacidosis,
Hemoglobin-based oxygen-carrying solutions, ammonia detoxification in, 484–485, 484t 263
390, 600–601 in chronic disease, 483–484 25-Hydroxycholecalciferol-1a-hydroxylase,
pulmonary edema due to, 395, 600–601 dietary, 479–480, 483–484, 484t, 485 41–42
for shock, 566, 567t enemas in, 484–485, 484t Hydroxyethyl starches, 336, 653–654
Hemolysis general considerations in, 482–483 adverse effects of, 399, 425, 490, 492,
hypophosphatemia and, 197–198 goals of, 482 657–658
pseudohyperkalemia and, 101 pathophysiology of, 482–483 anaphylaxis due to, 658
Hemolytic anemia, in liver disease, 492 spontaneous acute, 482 for ascites, 489–490, 492
Hemolytic transfusion reactions Hepatic lipidosis C2/C6 ratio and, 654
acute, 595–596 acid-base disturbances in, 477–478, 478f classification of, 653
delayed, 596 laboratory findings in, 465f, 474 clinical uses of, 655
Hemoperfusion Hepatic surgery, hypophosphatemia after, 200 coagulopathy due to, 399, 425, 492
adsorbents for, 704 Hepatobiliary system, physiology of, 456–462 degree of substitution and, 654